Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Centrally nucleated skeletal muscle fibers, Muscle fiber splitting, Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), and Increased endomysial connective tissue and others; and common findings: Interphalangeal joint contracture of finger, Distal muscle weakness, Ankle contracture, and Knee contracture and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 10 |
COL6A2 encodes collagen type VI alpha 2 chain (1,019 aa). Collagen VI acts as a cell-binding protein Highest expression in Cells Cultured fibroblasts (2,275 TPM) and Artery Aorta (1,878 TPM).
Bethlem myopathy 1B is associated with mutations in the COL6A2 gene on chromosome 21.
COL6A2 is classified as a druggable target (Druggable Genome category) with score 8.7.
Formal diagnostic criteria for collagen VI-related dystrophies (COL6-RDs) have not been established. The COL6-RDs are caused by a pathogenic variant(s) in COL6A1, COL6A2, or COL6A3 and represent a clinical spectrum including Bethlem muscular dystrophy at the milder end, Ullrich congenital muscular dystrophy (UCMD) at the more severe end, and intermediate COL6-RD, between Bethlem muscular dystrophy and UCMD. Note: Although these phenotypes are now recognized to comprise a continuum of overlapping phenotypes, the clinical designations are useful for providing a prognosis of future motor and pulmonary function and thus help to improve anticipatory clinical care.
No approved treatments are currently available for Bethlem myopathy 1B. The disease remains an area of unmet medical need.
Bethlem muscular dystrophy. To establish the extent of disease and needs in an individual diagnosed with Bethlem muscular dystrophy, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
Recommended Evaluations Following Initial Diagnosis in Individuals with Bethlem Muscular Dystrophy
Bethlem muscular dystrophy
Respiratory function surveillance is of utmost importance, since unrecognized respiratory insufficiency is a leading cause of morbidity and mortality. Pulmonary function tests (PFTs) should be performed in both the upright (seated) and supine (lying down) positions at least annually to monitor the FVC. For FVC measurements of 60% predicted or lower, NIV in the form of BiPAP should be planned for and initiated during a polysomnogram – with pressures adjusted while CO2 is monitored – in order to ensure that BiPAP pressures provide adequate ventilation.
No clinical trials have been registered for Bethlem myopathy 1B.
4 publications have been identified in PubMed for Bethlem myopathy 1B. Research spans Other (25%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Gallone A (2025). [PMID: 40550965](https://pubmed.ncbi.nlm.nih.gov/40550965/). *J Neurol*. [Other]
ElChoueiry M (2025). [PMID: 40792431](https://pubmed.ncbi.nlm.nih.gov/40792431/). *Animal Model Exp Med*. [Basic Science / Preclinical]
Maiga AB (2024). [PMID: 39523858](https://pubmed.ncbi.nlm.nih.gov/39523858/). *Mol Genet Genomic Med*. [Case Report / Case Series]
Mohan S (2024). [PMID: 39215466](https://pubmed.ncbi.nlm.nih.gov/39215466/). *Ann Clin Transl Neurol*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Online Mendelian Inheritance in Man
Common questions about Bethlem myopathy 1B
Bones and joints | 3 | Interphalangeal joint contracture of finger, Centrally nucleated skeletal muscle fibers, Abnormality of skeletal muscle fiber size |
Arms and legs | 1 | Interphalangeal joint contracture of finger |
Lab test results | 1 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration) |
Brain and nerves | 1 | Spinal rigidity |
The phenotypes associated with collagen VI-related dystrophies (COL6-RDs), once thought to be distinct entities, were clinically defined long before their molecular basis was discovered. The COL6-RDs are now recognized to comprise a continuum of overlapping phenotypes with Bethlem muscular dystrophy at the mild end, Ullrich congenital muscular dystrophy (UCMD) at the severe end, and phenotypes in between that are now collectively categorized within a subgroup called intermediate COL6-RD. These clinical phenotypic designations play an important role in providing a prognosis for future motor and pulmonary function and thus help in improving anticipatory clinical care.
The onset of symptoms of Bethlem muscular dystrophy can range from congenital to mid-adulthood. Obvi...
Source: GeneReviews — "Collagen VI-Related Dystrophies"
COL6-RDs can be caused by either autosomal dominant or autosomal recessive pathogenic variants in COL6A1, COL6A2, and COL6A3 . Pathogenic variants associated with autosomal dominant inheritance in COL6A1, COL6A2, and COL6A3 typically occur near the N terminal of the triple helical (TH) domain, which contains a critical region of 10 to 15 Gly-X-Y triplets; in-frame exon-skipping variants and glycine substitutions in this region tend to result in more severe phenotypes . Pathogenic variants associated with autosomal recessive inheritance are typically nonsense or frameshift variants . However, biallelic missense variants may be pathogenic when located near the C-terminal end of the TH domain, where they will be excluded from assembly .
COL6A1
Source: GeneReviews — "Collagen VI-Related Dystrophies"
Parents of individuals with recessively inherited COL6-RDs are usually heterozygous for a COL6A1, COL6A2, or COL6A3 pathogenic variant, but they do not manifest clinical symptoms of COL6-RD, even when predicted to be haploinsufficient for the respective gene. Individuals with dominantly inherited COL6-RDs are heterozygous for a COL6A1, COL6A2, or COL6A3 pathogenic variant and are typically symptomatic.
Source: GeneReviews — "Collagen VI-Related Dystrophies"
A COL6-RD should be suspected in individuals with the following , , and findings.
Clinical Findings
Source: GeneReviews — "Collagen VI-Related Dystrophies"
The differential diagnosis of the phenotypes observed in the collagen VI-related dystrophies (COL6-RDs) is discussed in this section. Of note, a normal-to-mildly elevated CK, suggestive findings on muscle MRI, lack of a cardiac phenotype, and normal-to-high intelligence are hallmarks of the COL6-RDs and help in distinguishing them from other disorders.
When joint contractures are subtle or missed, the major differential diagnoses are the limb-girdle muscular dystrophies (LGMDs) (see Limb-Girdle Muscular Dystrophy Overview). When joint contractures are a prominent feature, the major differential diagnoses are those summarized in .
Table 2a.
Disorders with Joint Contractures to Consider in the Differential Diagnosis of Bethlem Muscular Dystrophy
Source: GeneReviews — "Collagen VI-Related Dystrophies"
Genetic testing for COL6A2 is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment
| • Neuromuscular exam to evaluate degree distribution of muscle weakness its effects on mobility
Exam of joint contractures, esp assessing for asymmetry of Achilles tendon contractures
PT OT assessment
|
| Baseline polysomnogram w/continuous CO2 monitoring | During childhood to assess ventilation during deep sleep
Pulmonary function tests in both upright (seated) supine (lying down) positions w/forced vital capacity monitored closely | Starting at age 5 yrs
| Eval w/cardiologist incl echocardiogram EKG | To evaluate for right-sided heart strain in those w/respiratory insufficiency who are not using NIV or have inadequate BiPAP pressures
| Consultation w/clinical geneticist /or genetic counselor |
BiPAP = bilevel positive airway pressure; NIV = noninvasive ventilation; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "Collagen VI-Related Dystrophies"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Collagen VI-Related Dystrophies"
View trials for Bethlem myopathy 1B
Annual clinical and radiographic assessment of scoliosis
Annual cardiac evaluation with echocardiogram and EKG to evaluate for evidence of right-sided heart strain
Annual neuromuscular assessment by physical therapy and occupational therapy including an evaluation of the distribution of muscle weakness and joint contractures to inform recommendations for stretching regimens and mobility devices. Potential asymmetries of joint contractures are important to assess, given their effect on gait, sitting posture, and overall function.
UCMD / intermediate COL6-RD
Respiratory function surveillance is of utmost importance in UCMD and intermediate COL6-RD, since unrecognized or underrecognized respiratory insufficiency is the leading cause of morbidity and mortality. PFTs should be performed in both the upright (seated) and supine (lying down) positions every six months to monitor the FVC.
Source: GeneReviews — "Collagen VI-Related Dystrophies"
Phenotype severity distribution: 8 always present features, 5 common features.
AI-curated news mentioning Bethlem myopathy 1B
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.